BioAge Labs (BIOA)
Develops metabolic-disease drug candidates from human-aging biology.
$9.61
Pre-market−0.12 (−1.18%)
At close$9.73(+2.15%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions164 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 82.07% | 37.67M shares | |
| Insiders5 holders · as of Apr 24, 2026 | 8.56% | 3.93M shares | |
| Otherremainder | ≈ 9.37% | 4.30M shares |
45.90M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (45.90M in the company's Sep 3, 2026 report, 37.65M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Jun 30, 2026
164 holders · 37.67M shares · 29 new positions · 93 increased · 37 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ah Capital Management, L.L.C. | 3.23M | 7.04% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 2.85M | 6.21% | +581.3K | Aug 7, 2026 |
| Cormorant Asset Management, LP | 2.39M | 5.21% | −500.0K | Aug 14, 2026 |
| Sofinnova Investments, Inc. | 2.29M | 5.00% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 2.14M | 4.67% | +2.14Mnew | Aug 14, 2026 |
| Octagon Capital Advisors LP | 1.75M | 3.81% | 0 | Aug 14, 2026 |
| Ra Capital Management, L.P. | 1.67M | 3.64% | +21.0K | Aug 14, 2026 |
| Bioimpact Capital LLC | 1.67M | 3.63% | +1.67Mnew | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Marc Andreessenincl. AH Equity Partners LSV III, L.L.C., AH Equity Partners Bio III, L.L.C. +7 more | 9.00% | 3.23M | 13D | Oct 4, 2024 ↗ |
| Kristen Fortney | 7.20% | 2.70M | 13G | Feb 13, 2026 ↗ |
| Dr. James I. Healy (“Healy”)incl. Sofinnova Venture Partners XI, L.P. (“SVP XI”), Sofinnova Management XI, L.L.C. (“SM XI LLC”) +2 more | 6.70% | 2.30M | 13D | Sep 30, 2024 ↗ |
| Cormorant Asset Management, LP | 6.51% | 2.89M | 13G | May 15, 2026 ↗ |
| Peter Kolchinskyincl. RA Capital Healthcare Fund, L.P., Rajeev Shah +1 more | 6.20% | 2.21M | 13G | Oct 7, 2024 ↗ |
| BlackRock, Inc. | 5.03% | 2.24M | 13G | Apr 27, 2026 ↗ |
| VK Services, LLCincl. Khosla Ventures Opportunity I, LP, Khosla Ventures VI, LP +3 more | 5.00% | 1.80M | 13G | Nov 14, 2024 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 29, 2026 | Shane Bartonofficer: Principal Accounting Officer | Sale | 42,350 | $25.21 | 0 |
| Jun 30, 2026 | Shane Bartonofficer: Principal Accounting Officer | Sale | 20,216 | $25.19 | 0 |
| Apr 1, 2026 | Paul D. Rubinofficer: Chief Medical Officer | Sale | 8,820 | $17.81 | 0 |
| Mar 2, 2026 | Paul D. Rubinofficer: Chief Medical Officer | Sale | 7,433 | $20.30 | 0 |
| Feb 2, 2026 | Paul D. Rubinofficer: Chief Medical Officer | Sale | 7,433 | $18.75 | 0 |
| Jan 13, 2026 | Kristen Fortneydirector, officer: Chief Executive Officer | Sale | 233,107 | $18.12 | 976,949 |
| Jan 13, 2026 | Dov A. Md Goldsteinofficer: Chief Financial Officer | Sale · 4 lots | 27,000 | $19.70 | 22,408 |
| Jan 2, 2026 | Paul D. Rubinofficer: Chief Medical Officer | Sale | 7,433 | $12.85 | 0 |
| Dec 9, 2025 | Paul D. Rubinofficer: Chief Medical Officer | Sale | 18,000 | $12.00 | 0 |
| Dec 4, 2025 | Paul D. Rubinofficer: Chief Medical Officer | Sale | 68,897 | $10.19 | 0 |
CongressHouse and Senate disclosures
Not reported.